Motixafortide Side Effects: Safety Signals and Warnings
Motixafortide safety concerns are compound-specific. The main listed side effects are Injection site reactions (erythema, pain, pruritus), Diarrhea, and Musculoskeletal pain. The main warning signals are Anaphylaxis and serious hypersensitivity reactions reported - observe for at least 1 hour after injection, Splenic enlargement/rupture possible with G-CSF combination, and Tumor cell mobilization theoretically possible in hematologic malignancies.
Direct Answer
Motixafortide (Aphexda) is FDA-approved in combination with G-CSF for hematopoietic stem cell mobilization prior to autologous transplantation in multiple myeloma. The Phase 3 GENESIS trial showed significantly more CD34+ cells mobilized with fewer apheresis sessions versus G-CSF alone. A well-evidenced stem cell mobilization enhancer for a specific transplant medicine context.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Immune Support
- Best for
- Hematopoietic stem cell mobilization (multiple myeloma transplant), CXCR4 antagonist pharmacology
Reported Side Effects
- Injection site reactions (erythema, pain, pruritus)
- Diarrhea
- Musculoskeletal pain
- Dizziness
- Nausea
- Hypersensitivity reactions
Warnings
- Anaphylaxis and serious hypersensitivity reactions reported - observe for at least 1 hour after injection
- Splenic enlargement/rupture possible with G-CSF combination
- Tumor cell mobilization theoretically possible in hematologic malignancies
- Not studied in patients with sickle cell disease
Known or Plausible Interactions
- G-CSF (used in combination - additive mobilization)
- Chemotherapy mobilization regimens (may be used sequentially)
- CXCR4-dependent medications
Regulatory Context
FDA-approved (September 2023) in combination with G-CSF for mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma. Available by prescription only. Marketed as Aphexda by BioLineRx.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Stem Cell Mobilization (Level A), Engraftment Success (Level A), and Injection Site Reactions (Level A) |
| Primary citation count | 2 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Motixafortide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/motixafortide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.